Clinical Trials Directory

Trials / Unknown

UnknownNCT02929836

Catheter Ablation of Longstanding Persistent Atrial Fibrillation

Optimal Ablation Endpoint for Longstanding Persistent Atrial Fibrillation: a Randomized Prospective Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
450 (estimated)
Sponsor
Shanghai Chest Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This randomized prospective study compared three ablation strategies in patients with longstanding persistent atrial fibrillation (LPeAF). It also explored the best procedural endpoint from among the following: circumferential pulmonary vein isolation (PVI)+left atrial (LA) linear lesions (roof line, mitral isthmus)+complex fractionated atrial electrogram (CFAE) ablation, PVI+LA linear lesions +cavotricuspid isthmus (CTI) ablation +CFAE ablation, and PVI+CFAE ablation.

Detailed description

Patients were randomized into three ablation groups: group A (n=100): PVI+LA linear ablation (roof line and mitral isthmus) +CFAE ablation; group B (n=100): PVI+linear ablation (roof line, mitral isthmus, and CTI) +CFAE ablation; group C (n=100), PVI+CFAE ablation.

Conditions

Interventions

TypeNameDescription
PROCEDUREPVIPVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
PROCEDURELA linear ablationLA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
PROCEDURECFAE ablationAblation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
PROCEDURElinear ablationRight atrial CTI ablation was performed during SR.
DEVICECARTO3 dimensional mapping system

Timeline

Start date
2016-05-01
Primary completion
2017-05-01
Completion
2018-10-01
First posted
2016-10-11
Last updated
2016-10-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02929836. Inclusion in this directory is not an endorsement.